Akseli Hemminki. TILT Biotherapeutics CEO

On­colyt­ic virus start­up TILT rais­es €22M to ad­vance can­cer ther­a­pies

Fin­land-based TILT Bio­ther­a­peu­tics an­nounced to­day it raised €22 mil­lion in the fi­nal close of a sec­ond round of fi­nanc­ing to push its on­colyt­ic virus pipeline in­to Phase II tri­als. The com­pa­ny raised €10 mil­lion in the first round in June of last year.

A chunk of the sec­ond round, €5.9 mil­lion, comes from the Eu­ro­pean In­no­va­tion Coun­cil Fund with an­oth­er €2.1 mil­lion grant from EIC’s Ac­cel­er­a­tor pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.